Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial

IMPORTANCE: SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2. OBJECTIVE: To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19. DESIGN, SETTING, AND PARTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickols, Nicholas G., Mi, Zhibao, DeMatt, Ellen, Biswas, Kousick, Clise, Christina E., Huggins, John T., Maraka, Spyridoula, Ambrogini, Elena, Mirsaeidi, Mehdi S., Levin, Ellis R., Becker, Daniel J., Makarov, Danil V., Adorno Febles, Victor, Belligund, Pooja M., Al-Ajam, Mohammad, Muthiah, Muthiah P., Montgomery, Robert B., Robinson, Kyle W., Wong, Yu-Ning, Bedimo, Roger J., Villareal, Reina C., Aguayo, Samuel M., Schoen, Martin W., Goetz, Matthew B., Graber, Christopher J., Bhattacharya, Debika, Soo Hoo, Guy, Orshansky, Greg, Norman, Leslie E., Tran, Samantha, Ghayouri, Leila, Tsai, Sonny, Geelhoed, Michelle, Rettig, Mathew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020208/
https://www.ncbi.nlm.nih.gov/pubmed/35438754
http://dx.doi.org/10.1001/jamanetworkopen.2022.7852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020208/
https://www.ncbi.nlm.nih.gov/pubmed/35438754
http://dx.doi.org/10.1001/jamanetworkopen.2022.7852

Ejemplares similares